Cargando…

A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma

BACKGROUND: We aimed to construct a clinical-radiomics nomogram to predict disease-free survival (DFS) and the added survival benefit of adjuvant chemotherapy (ACT) for node-negative, early-stage (I–II) lung adenocarcinoma (ADC). METHODS: In this retrospective study including 310 patients from two i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiaoling, Lv, Wenzhi, Wang, Cong, Tu, Dehao, Qiao, Jinhan, Fan, Chanyuan, Niu, Jiandong, Zhou, Wen, Liu, Qiuyu, Xia, Liming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828517/
https://www.ncbi.nlm.nih.gov/pubmed/35242363
http://dx.doi.org/10.21037/jtd-21-1520
_version_ 1784647864290377728
author Ma, Xiaoling
Lv, Wenzhi
Wang, Cong
Tu, Dehao
Qiao, Jinhan
Fan, Chanyuan
Niu, Jiandong
Zhou, Wen
Liu, Qiuyu
Xia, Liming
author_facet Ma, Xiaoling
Lv, Wenzhi
Wang, Cong
Tu, Dehao
Qiao, Jinhan
Fan, Chanyuan
Niu, Jiandong
Zhou, Wen
Liu, Qiuyu
Xia, Liming
author_sort Ma, Xiaoling
collection PubMed
description BACKGROUND: We aimed to construct a clinical-radiomics nomogram to predict disease-free survival (DFS) and the added survival benefit of adjuvant chemotherapy (ACT) for node-negative, early-stage (I–II) lung adenocarcinoma (ADC). METHODS: In this retrospective study including 310 patients from two independent cohorts, the CT-derived radiomics features were selected by least absolute shrinkage and selection operator Cox regression to generate a radiomics signature associated with DFS. The radiomics signature was incorporated to construct a clinical-radiomics nomogram along with the independent clinical risk predictors. The model performance was evaluated with reference to discrimination quantified by Harrell concordance index (C-index), integrated discrimination improvement (IDI) and net reclassification index (NRI), calibration and clinical utility. The risk score (RS) for clinical-radiomics nomogram was calculated. The association between ACT and survival benefit was assessed in high and low RS subgroup. RESULTS: The clinical-radiomics nomogram achieved the highest C-index of 0.822 [95% confidence interval (CI): 0.769, 0.876] in training cohort and 0.802 (95% CI: 0.716, 0.888) in validation cohort. The incorporation of radiomics signature into clinical-radiomics nomogram showed an incremental benefit over clinical nomogram according to the improved NRI and IDI. The calibration curves and decision curve analysis further verified the clinical utility of clinical-radiomics nomogram. Further, patients with high RS based on clinical-radiomics nomogram were more prone to benefit from ACT. CONCLUSIONS: The clinical-radiomics nomogram approach can feasibly conduct risk prediction and have potential to identify the beneficiaries of ACT among patients with node-negative, early-stage ADC, which might serve as a helpful tool in informing therapeutic decision-making.
format Online
Article
Text
id pubmed-8828517
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-88285172022-03-02 A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma Ma, Xiaoling Lv, Wenzhi Wang, Cong Tu, Dehao Qiao, Jinhan Fan, Chanyuan Niu, Jiandong Zhou, Wen Liu, Qiuyu Xia, Liming J Thorac Dis Original Article BACKGROUND: We aimed to construct a clinical-radiomics nomogram to predict disease-free survival (DFS) and the added survival benefit of adjuvant chemotherapy (ACT) for node-negative, early-stage (I–II) lung adenocarcinoma (ADC). METHODS: In this retrospective study including 310 patients from two independent cohorts, the CT-derived radiomics features were selected by least absolute shrinkage and selection operator Cox regression to generate a radiomics signature associated with DFS. The radiomics signature was incorporated to construct a clinical-radiomics nomogram along with the independent clinical risk predictors. The model performance was evaluated with reference to discrimination quantified by Harrell concordance index (C-index), integrated discrimination improvement (IDI) and net reclassification index (NRI), calibration and clinical utility. The risk score (RS) for clinical-radiomics nomogram was calculated. The association between ACT and survival benefit was assessed in high and low RS subgroup. RESULTS: The clinical-radiomics nomogram achieved the highest C-index of 0.822 [95% confidence interval (CI): 0.769, 0.876] in training cohort and 0.802 (95% CI: 0.716, 0.888) in validation cohort. The incorporation of radiomics signature into clinical-radiomics nomogram showed an incremental benefit over clinical nomogram according to the improved NRI and IDI. The calibration curves and decision curve analysis further verified the clinical utility of clinical-radiomics nomogram. Further, patients with high RS based on clinical-radiomics nomogram were more prone to benefit from ACT. CONCLUSIONS: The clinical-radiomics nomogram approach can feasibly conduct risk prediction and have potential to identify the beneficiaries of ACT among patients with node-negative, early-stage ADC, which might serve as a helpful tool in informing therapeutic decision-making. AME Publishing Company 2022-01 /pmc/articles/PMC8828517/ /pubmed/35242363 http://dx.doi.org/10.21037/jtd-21-1520 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Ma, Xiaoling
Lv, Wenzhi
Wang, Cong
Tu, Dehao
Qiao, Jinhan
Fan, Chanyuan
Niu, Jiandong
Zhou, Wen
Liu, Qiuyu
Xia, Liming
A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma
title A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma
title_full A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma
title_fullStr A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma
title_full_unstemmed A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma
title_short A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma
title_sort potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828517/
https://www.ncbi.nlm.nih.gov/pubmed/35242363
http://dx.doi.org/10.21037/jtd-21-1520
work_keys_str_mv AT maxiaoling apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT lvwenzhi apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT wangcong apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT tudehao apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT qiaojinhan apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT fanchanyuan apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT niujiandong apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT zhouwen apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT liuqiuyu apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT xialiming apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT maxiaoling potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT lvwenzhi potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT wangcong potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT tudehao potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT qiaojinhan potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT fanchanyuan potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT niujiandong potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT zhouwen potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT liuqiuyu potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma
AT xialiming potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma